



February 23, 2016

Press release

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Enhances Operations in the United States

Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka, Japan: President & Representative Director Masayuki Mitsuka) announced today that it has established MT Pharma America, Inc. (MTPA), with a view to commercializing approved pharmaceutical products in the United States as a wholly-owned subsidiary of MTPC's 100% owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.

MTPC's priority will be to seek FDA approval and launch Edaravone (development code: MCI-186) in the U.S. for the treatment of patients with amyotrophic lateral sclerosis (ALS), for which it has been approved and marketed as its additional indication in Japan in June 2015. MTPA will structure the organization by enhancing its functions and personnel resources and proceed with preparations to launch MCI-186.

MTPC has announced the "Medium-Term Management Plan 16-20: Open Up the Future" starting in April, which focuses on the acceleration of the U.S. business as one of the top priorities. MTPC will launch MCI-186 (pending FDA approval) as its first step in building the U.S. business foundation and will expand its product line utilizing the collaborations with its partners, aiming to enhance the foundation focused on specialty pharmaceuticals in the U.S.

<<For Details, Contact the Following Section>>

Corporate Communications Department

Tel +81-6-6205-5211

< Outline of the new company >

Company name: MT Pharma America, Inc.

Establishment date: February 8, 2016

Location: New Jersey, U.S.A.

President: Atsushi Fujimoto


Invested capital: US\$5,000,100

Shareholding: Mitsubishi Tanabe Pharma Corporation

(Indirect ownership through MTPC's 100% owned US holding company)

Contact: <http://www.mt-pharma.co.jp/shared/show.php?url=/e/company/group.html>

< Organization of US group companies >



About ALS

ALS is a progressive and intractable disease characterized by muscular atrophy and weakness. Disease progression is comparatively rapid, and if ventilators are used, survival time is said to typically be two to five years, however there is significant variation among individuals.

About Edaravone (development code: MCI-186)

MTPC received manufacturing and marketing authorization of Edaravone for a treatment of acute stroke in Japan in 2001, which has been sold as Radicut[®] infusion inj. Radicut[®] infusion bag was also approved in 2010 and has been sold in Japan.

Radicut[®] was designated as orphan drug for a treatment of ALS in Japan in 2005.